



REMARKS

This is a preliminary amendment in which the Applicant has eliminated multiple dependencies.

A favorable first action is respectfully requested.

If, for any reason, the Examiner is of the opinion that a telephone conversation with the Applicant's representative would expedite prosecution, the Examiner is invited to contact the undersigned at 617-573-7851.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Timothy J. Oyer", written over a horizontal line.

Timothy J. Oyer, Reg. No. 36,628  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210  
Tel. 617-720-3500

Docket No.: M1015/7034  
Date: May 29, 2001

**MARKED-UP CLAIMS**

103. (Amended) A [kit, method, or composition as in any preceding claim] method as in claim 1, wherein the drug is selected from the group consisting of Atenolol, pindolol, histamine, methyl dihydrochloride, atenolol, 4-aminopyridine, physostigmine, and Tetracaine Hydrochloride.

104. (Amended) A [kit, method, or composition as in any preceding claim] method as in claim 1, wherein the drug is selected from the group consisting of sulpiride, uracil, 5-trifluoromethyl-5,6-dihydro, Atenolol, pindolol, BRL 37344 sodium, piperazine (2:1 ratio of 1-(4-hydroxy-3-methoxyphenyl)-1,2-ethanediol and diethyldiazene), cimetidine, methyl norepinephrine, oxotremorine methiodide, physostigmine, 4-aminopyridine, 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5- (trifluoromethyl)-2H-benzimidazol-2-one), and erbstatin analog.